EN | RU
EN | RU

Help Support

Back

Cardiovascular outcomes with Ticagrelor vs Clopidogrel in diabetes people with ACS

Acute Coronary Syndrome Acute Coronary Syndrome
Acute Coronary Syndrome Acute Coronary Syndrome

This study was carried out to systematically evaluate the cardiovascular outcomes reported with Ticagrelor vs Clopidogrel in type 2 diabetes mellitus (T2DM) people suffering from acute coronary syndrome (ACS).

See All

Key take away

In type 2 diabetes mellitus people with acute coronary syndrome, there is a considerably minimized chance of major adverse cardiovascular outcomes encompassing all-cause mortality with Ticagrelor than Clopidogrel.

Background

This study was carried out to systematically evaluate the cardiovascular outcomes reported with Ticagrelor vs Clopidogrel in type 2 diabetes mellitus (T2DM) people suffering from acute coronary syndrome (ACS).

Method

In this meta-analysis, electronic databases were searched for articles comparing the cardiovascular outcomes seen with Ticagrelor with Clopidogrel in T2DM-affected people. RevMan 5.4 software was used to conduct the statistical analysis. The data were examined using a statistical model with a random effect. Using risk ratios (RR) and 95% confidence intervals, the results were presented.

Result

A total of 5868 T2DM patients were incorporated, of whom 3924 participants received Clopidogrel and 1944 participants received Ticagrelor. Ticagrelor, when compared to Clopidogrel, had a considerably decreased risk of cardiac death (RR: 0.60), major adverse cardiac events (MACEs) (RR: 0.64), and all-cause mortality (RR: 0.65). But, the risks of stroke (RR: 0.56), stent thrombosis (RR: 0.70), reinfarction (RR: 0.85), and recurrent revascularization (RR: 1.48) were comparable. While the risk for major bleeding (RR: 1.08) was not statistically different, Ticagrelor was linked to a considerably greater risk of minor bleeding (RR: 1.53).

Conclusion

A considerably decreased major adverse cardiovascular events risks, encompassing all-cause mortality, was seen with Ticagrelor use compared to Clopidogrel use in T2DM patients with ACS. But, T2DM people who were given Ticagrelor demonstrated a noticeably raised risk of minor bleeding.

Source:

Diabetes Therapy

Article:

Cardiovascular Outcomes Observed with Ticagrelor versus Clopidogrel in Type 2 Diabetes Mellitus Patients with Acute Coronary Syndrome: A Meta-analysis

Authors:

Zhiming Jiang et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: